Limitless Potential.
Precision Design.
Enduring Impact.
Aiming to transform the treatment of autoimmune diseases and cancer by developing allogeneic, iPSC-derived cell therapies.
PRESS RELEASES + EVENTS
view all
November 25, 2025
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology…
November 13, 2025
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug…
About us
We are building an industry-leading, allogeneic, iPSC-derived cell therapy platform for autoimmune diseases and cancer.
OUR SCIENCE
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.
